Table 3.
Best Real-World Tumor Response to First-Line Pembrolizumab Monotherapy, Overall and by Age Group
| Real-World Tumor Response | All Patients (N = 441) |
Age < 75 y (n = 303) | Age ≥ 75 y (n = 138) |
|---|---|---|---|
| rwTumor response, n | 166 | 117 | 49 |
| rwTRR, % (95% Clopper-Pearson CI) | 37.6 (33.1–42.3) | 38.6 (33.1–44.4) | 35.5 (27.6–44.1) |
| rwDisease control, n | 237 | 167 | 70 |
| rwDCR, % (95% Clopper-Pearson CI) | 53.7 (49.0–58.5) | 55.1 (49.3–60.8) | 50.7 (42.1–59.3) |
| rwDuration of response (rwDoR), n | 164 | 116 | 48 |
| Events, n (%) | 68 (41.5) | 48 (41.4) | 20 (41.7) |
| Median rwDoR (95% CI), months | 16.0 (12.9–NR) | 15.2 (11.5–NR) | 16.0 (9.8–NR) |
CI, confidence interval; NR, not reached; rwDCR, real-world disease control rate; rwDoR, real-world duration of response; rwTRR, real-world tumor response rate.